首页 > 最新文献

Archives of pathology & laboratory medicine最新文献

英文 中文
Update on Sinonasal Tract Malignancies: Advances in Diagnostic Modalities. 鼻窦道恶性肿瘤的最新进展:诊断方式的进展。
IF 3.7 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-10-01 DOI: 10.5858/arpa.2022-0447-RA
Maria A Gubbiotti, Virginia LiVolsi, Kathleen T Montone

Context.—: Sinonasal tract malignancies are rare cancers with frequent morphologic overlap. Given the similar histologic profiles seen in many of these entities, they often present a diagnostic challenge to the practicing pathologist.

Objective.—: To provide a streamlined algorithm using histologic clues, immunohistochemical profiles, and molecular assays to aid in diagnosis of these lesions.

Data sources.—: Sources were the World Health Organization Tumor Classification, literature review, and institutional experience.

Conclusions.—: Although many sinonasal tract malignancies show similar histology, distinct immunohistochemical and molecular profiles can help parse out differences, thereby facilitating diagnosis for the pathologist.

背景鼻窦道恶性肿瘤是一种罕见的癌症,其形态经常发生重叠。鉴于许多此类肿瘤具有相似的组织学特征,它们常常给执业病理学家带来诊断上的挑战:利用组织学线索、免疫组化图谱和分子检测提供一种简化算法,以帮助诊断这些病变:数据来源包括世界卫生组织肿瘤分类、文献综述和机构经验:尽管许多鼻窦道恶性肿瘤显示出相似的组织学特征,但不同的免疫组化和分子图谱有助于区分差异,从而为病理学家的诊断提供便利。
{"title":"Update on Sinonasal Tract Malignancies: Advances in Diagnostic Modalities.","authors":"Maria A Gubbiotti, Virginia LiVolsi, Kathleen T Montone","doi":"10.5858/arpa.2022-0447-RA","DOIUrl":"10.5858/arpa.2022-0447-RA","url":null,"abstract":"<p><strong>Context.—: </strong>Sinonasal tract malignancies are rare cancers with frequent morphologic overlap. Given the similar histologic profiles seen in many of these entities, they often present a diagnostic challenge to the practicing pathologist.</p><p><strong>Objective.—: </strong>To provide a streamlined algorithm using histologic clues, immunohistochemical profiles, and molecular assays to aid in diagnosis of these lesions.</p><p><strong>Data sources.—: </strong>Sources were the World Health Organization Tumor Classification, literature review, and institutional experience.</p><p><strong>Conclusions.—: </strong>Although many sinonasal tract malignancies show similar histology, distinct immunohistochemical and molecular profiles can help parse out differences, thereby facilitating diagnosis for the pathologist.</p>","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"1082-1091"},"PeriodicalIF":3.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9111639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Update on Salivary Gland Fine-Needle Aspiration and the Milan System for Reporting Salivary Gland Cytopathology. 唾液腺细针抽吸术和唾液腺细胞病理学米兰报告系统的最新进展。
IF 3.7 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-10-01 DOI: 10.5858/arpa.2022-0529-RA
Marc Pusztaszeri, Esther Diana Rossi, William C Faquin

Context.—: Fine-needle aspiration (FNA) is a well-established procedure for the diagnosis and management of salivary gland lesions, despite challenges imposed by salivary gland tumor diversity, complexity, and cytomorphologic overlap. Until recently, the reporting of salivary gland FNA specimens was inconsistent among different institutions throughout the world, leading to diagnostic confusion among pathologists and clinicians. In 2015, an international group of pathologists initiated the development of an evidence-based tiered classification system for reporting salivary gland FNA specimens, the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC). The MSRSGC consists of 6 diagnostic categories, which incorporate the morphologic heterogeneity and overlap among various nonneoplastic, benign, and malignant lesions of the salivary glands. In addition, each MSRSGC diagnostic category is associated with a risk of malignancy and management recommendations.

Objective.—: To review the current status of salivary gland FNA, core needle biopsies, ancillary studies, and the beneficial role of the MSRSGC in providing a framework for reporting salivary gland lesions and guiding clinical management.

Data sources.—: Literature review and personal institutional experience.

Conclusions.—: The main goal of the MSRSGC is to improve communication between cytopathologists and treating clinicians, while also facilitating cytologic-histologic correlation, quality improvement, and research. Since its implementation, the MSRSGC has gained international acceptance as a tool to improve reporting standards and consistency in this complex diagnostic area, and it has been endorsed by the 2021 American Society of Clinical Oncology management guidelines for salivary gland cancer. The large amount of data from published studies using MSRSGC served as a basis for the recent update of the MSRSGC.

背景尽管涎腺肿瘤具有多样性、复杂性和细胞形态学重叠性等特点,但细针穿刺术(FNA)是诊断和治疗涎腺病变的一种行之有效的方法。直到最近,世界各地不同机构对唾液腺 FNA 标本的报告仍不一致,导致病理学家和临床医生在诊断上产生困惑。2015 年,一个由病理学家组成的国际小组发起制定了一套基于证据的分级分类系统,用于报告唾液腺 FNA 标本,即米兰唾液腺细胞病理学报告系统(MSRSGC)。MSRSGC 包括 6 个诊断类别,其中包含了唾液腺各种非肿瘤性、良性和恶性病变的形态异质性和重叠性。此外,MSRSGC 的每个诊断类别都与恶性肿瘤的风险和管理建议相关联:回顾唾液腺 FNA、核心针活检、辅助研究的现状,以及 MSRSGC 在提供唾液腺病变报告框架和指导临床管理方面的有益作用:文献综述和个人机构经验:MSRSGC的主要目标是改善细胞病理学家与临床治疗医生之间的沟通,同时促进细胞学与病理学的相关性、质量改进和研究。自实施以来,MSRSGC 已获得国际认可,成为在这一复杂诊断领域提高报告标准和一致性的工具,并得到了 2021 年美国临床肿瘤学会唾液腺癌管理指南的认可。使用 MSRSGC 的大量已发表研究数据是最近更新 MSRSGC 的基础。
{"title":"Update on Salivary Gland Fine-Needle Aspiration and the Milan System for Reporting Salivary Gland Cytopathology.","authors":"Marc Pusztaszeri, Esther Diana Rossi, William C Faquin","doi":"10.5858/arpa.2022-0529-RA","DOIUrl":"10.5858/arpa.2022-0529-RA","url":null,"abstract":"<p><strong>Context.—: </strong>Fine-needle aspiration (FNA) is a well-established procedure for the diagnosis and management of salivary gland lesions, despite challenges imposed by salivary gland tumor diversity, complexity, and cytomorphologic overlap. Until recently, the reporting of salivary gland FNA specimens was inconsistent among different institutions throughout the world, leading to diagnostic confusion among pathologists and clinicians. In 2015, an international group of pathologists initiated the development of an evidence-based tiered classification system for reporting salivary gland FNA specimens, the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC). The MSRSGC consists of 6 diagnostic categories, which incorporate the morphologic heterogeneity and overlap among various nonneoplastic, benign, and malignant lesions of the salivary glands. In addition, each MSRSGC diagnostic category is associated with a risk of malignancy and management recommendations.</p><p><strong>Objective.—: </strong>To review the current status of salivary gland FNA, core needle biopsies, ancillary studies, and the beneficial role of the MSRSGC in providing a framework for reporting salivary gland lesions and guiding clinical management.</p><p><strong>Data sources.—: </strong>Literature review and personal institutional experience.</p><p><strong>Conclusions.—: </strong>The main goal of the MSRSGC is to improve communication between cytopathologists and treating clinicians, while also facilitating cytologic-histologic correlation, quality improvement, and research. Since its implementation, the MSRSGC has gained international acceptance as a tool to improve reporting standards and consistency in this complex diagnostic area, and it has been endorsed by the 2021 American Society of Clinical Oncology management guidelines for salivary gland cancer. The large amount of data from published studies using MSRSGC served as a basis for the recent update of the MSRSGC.</p>","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"1092-1104"},"PeriodicalIF":3.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9522543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BRAF Exon 15 Mutations in the Evaluation of Well-Differentiated Epithelial Nephroblastic Neoplasms in Children: A Report From the Children's Oncology Group Study AREN03B2. 儿童分化良好的上皮性肾母细胞肿瘤评估中的 BRAF 15 号外显子突变:儿童肿瘤学组 AREN03B2 研究报告》。
IF 3.7 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-10-01 DOI: 10.5858/arpa.2022-0528-OA
Jeffery A Goldstein, Lindsay A Renfro, Lawrence J Jennings, Elizabeth A Mullen, James Geller, Kelly Vallance, Conrad V Fernandez, Elizabeth J Perlman

Context.—: The distinction between well-differentiated epithelial favorable-histology Wilms tumor (EFHWT) and metanephric adenoma (MA) in children has historically been determined by the required absence of both a fibrous pseudocapsule and mitotic activity in MA. More recently these features have been allowed in adult MA. Mutations in exon 15 of the BRAF gene are reported in up to 88% of MAs but have not been reported in EFHWTs in children lacking MA features.

Objective.—: To clarify the pathologic and molecular features used to distinguish between pediatric MA and EFHWT.

Design.—: Stage I epithelial tumors classified as EFHWT on central review (36 patients) were identified from the Children's Oncology Group AREN03B2 study. Thirteen tumors had morphologic features overlapping those of MA and 23 lacked such features; 35 of 36 had tissue available for sequencing of BRAF.

Results.—: Patients with EFHWTs with MA features (13) were older (mean, 8.4 versus 1.9 years; P < .001), had smaller tumor diameters (mean, 6.0 versus 9.7 cm; P < .001), and had fewer mitoses (mean, 1 versus 48 mitoses per 10 high-power fields; P < .001) than patients with EFHWT lacking MA features (23). All EFHWTs with MA features contained at least a partial fibrous pseudocapsule; 7 of 12 (58%) had a BRAF exon 15 mutation. No BRAF exon 15 mutations were identified in 23 EFHWTs lacking MA features. None of the 13 EFHWT patients with MA features have experienced relapse (median follow-up 5.9 years).

Conclusions.—: Pediatric epithelial neoplasms with features of MA that show partial encapsulation and/or modest mitotic activity may be classified as MAs. Although BRAF mutation supports the diagnosis of MA, it is not required for the diagnosis.

背景:儿童分化良好的上皮好组学 Wilms 肿瘤(EFHWT)与肾上腺瘤(MA)的区别,历来是根据肾上腺瘤必须没有纤维假包囊和有丝分裂活动来确定的。最近,成人肾腺瘤也出现了这些特征。据报道,BRAF 基因第 15 外显子的突变在高达 88% 的 MA 中存在,但在 EFHWT 中尚未见报道:明确用于区分儿科 MA 和 EFHWT 的病理和分子特征:从儿童肿瘤学组 AREN03B2 研究中确定了经中央审查归类为 EFHWT 的 I 期上皮肿瘤(36 例患者)。其中 13 例肿瘤的形态学特征与 MA 重叠,23 例肿瘤缺乏此类特征;36 例肿瘤中有 35 例肿瘤组织可用于 BRAF 测序:与缺乏 MA 特征的 EFHWT 患者(23 例)相比,具有 MA 特征的 EFHWT 患者(13 例)年龄较大(平均 8.4 岁对 1.9 岁;P < .001),肿瘤直径较小(平均 6.0 厘米对 9.7 厘米;P < .001),有丝分裂较少(平均每 10 个高倍视野中有 1 个有丝分裂对 48 个有丝分裂;P < .001)。所有具有 MA 特征的 EFHWT 至少含有部分纤维性假包囊;12 例中有 7 例(58%)发生了 BRAF 15 号外显子突变。在 23 例无 MA 特征的 EFHWT 中未发现 BRAF 15 号外显子突变。在13名具有MA特征的EFHWT患者中,没有一人复发(中位随访5.9年):结论:具有MA特征的小儿上皮性肿瘤表现为部分包膜和/或适度的有丝分裂活动,可归类为MA。虽然 BRAF 基因突变有助于 MA 的诊断,但并非诊断的必要条件。
{"title":"BRAF Exon 15 Mutations in the Evaluation of Well-Differentiated Epithelial Nephroblastic Neoplasms in Children: A Report From the Children's Oncology Group Study AREN03B2.","authors":"Jeffery A Goldstein, Lindsay A Renfro, Lawrence J Jennings, Elizabeth A Mullen, James Geller, Kelly Vallance, Conrad V Fernandez, Elizabeth J Perlman","doi":"10.5858/arpa.2022-0528-OA","DOIUrl":"10.5858/arpa.2022-0528-OA","url":null,"abstract":"<p><strong>Context.—: </strong>The distinction between well-differentiated epithelial favorable-histology Wilms tumor (EFHWT) and metanephric adenoma (MA) in children has historically been determined by the required absence of both a fibrous pseudocapsule and mitotic activity in MA. More recently these features have been allowed in adult MA. Mutations in exon 15 of the BRAF gene are reported in up to 88% of MAs but have not been reported in EFHWTs in children lacking MA features.</p><p><strong>Objective.—: </strong>To clarify the pathologic and molecular features used to distinguish between pediatric MA and EFHWT.</p><p><strong>Design.—: </strong>Stage I epithelial tumors classified as EFHWT on central review (36 patients) were identified from the Children's Oncology Group AREN03B2 study. Thirteen tumors had morphologic features overlapping those of MA and 23 lacked such features; 35 of 36 had tissue available for sequencing of BRAF.</p><p><strong>Results.—: </strong>Patients with EFHWTs with MA features (13) were older (mean, 8.4 versus 1.9 years; P < .001), had smaller tumor diameters (mean, 6.0 versus 9.7 cm; P < .001), and had fewer mitoses (mean, 1 versus 48 mitoses per 10 high-power fields; P < .001) than patients with EFHWT lacking MA features (23). All EFHWTs with MA features contained at least a partial fibrous pseudocapsule; 7 of 12 (58%) had a BRAF exon 15 mutation. No BRAF exon 15 mutations were identified in 23 EFHWTs lacking MA features. None of the 13 EFHWT patients with MA features have experienced relapse (median follow-up 5.9 years).</p><p><strong>Conclusions.—: </strong>Pediatric epithelial neoplasms with features of MA that show partial encapsulation and/or modest mitotic activity may be classified as MAs. Although BRAF mutation supports the diagnosis of MA, it is not required for the diagnosis.</p>","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"e362-e366"},"PeriodicalIF":3.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11186972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138794576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Creation of a Quality Payment Program Measure for Mismatch Repair or Microsatellite Instability Biomarker Testing Status in Colorectal, Endometrial, Gastroesophageal, or Small Bowel Carcinoma. 针对结直肠癌、子宫内膜癌、胃食管癌或小肠癌的错配修复或微卫星不稳定性生物标记物检测状况制定质量付费计划衡量标准。
IF 3.7 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-06-01 DOI: 10.5858/arpa.2022-0418-OA
Gregary T Bocsi, Jennifer Laudadio, Richa Jain, Sarah M Eakin, Amarpreet Bhalla, Jonathan A Rosenberg, Jennifer K Maratt, Sonia S Kupfer, David A Leiman, Diana M Cardona

Context.—: Quality measures that are supported by evidence-based clinical practice guidelines are preferred for assessing the quality of pathologists' practices. Careful testing of a measure ensures that scores obtained by that measure reflect the quality of a pathologist's practice.

Objective.—: To specify a new quality measure and to demonstrate through testing that it is suitable for measuring pathologists' appropriate incorporation of information regarding microsatellite instability (MSI) and/or mismatch repair (MMR) status in pathology reports for colorectal, endometrial, gastroesophageal, and small bowel carcinoma.

Design.—: The College of American Pathologists collaborated with the American Gastroenterological Association to specify and test the new measure. Face validity testing was used to investigate the validity of the measure. Feasibility testing was conducted to understand if data elements required by the measure specification were readily accessible. Signal-to-noise analysis was used to characterize the measure's reliability.

Results.—: Guideline recommendations for MSI and/or MMR testing supported specifications for the measure. Face validity testing indicated that the measure could distinguish the quality of care provided. Data elements required by the measure specification were found to be accessible, which supported the measure's feasibility. Reliability testing showed that differences in measure score were attributable to real differences in performance rather than random variation in scoring.

Conclusions.—: The Mismatch Repair or Microsatellite Instability Biomarker Testing Status in Colorectal Carcinoma, Endometrial, Gastroesophageal, or Small Bowel Carcinoma measure was appropriately specified, and testing demonstrated that it is well suited for characterizing the quality of pathologists' communication of MMR and/or MSI status.

背景:有循证临床实践指南支持的质量测量方法是评估病理学家诊疗质量的首选。对衡量标准进行仔细测试可确保该衡量标准所获得的分数能够反映病理学家的工作质量:明确一项新的质量测量方法,并通过测试证明该方法适用于测量病理学家在结直肠癌、子宫内膜癌、胃食管癌和小肠癌的病理报告中适当纳入微卫星不稳定性(MSI)和/或错配修复(MMR)状态信息的情况:美国病理学家学会与美国胃肠病学协会合作制定并测试了新的测量方法。表面效度测试用于调查测量的有效性。进行了可行性测试,以了解测量规范所要求的数据元素是否易于获取。信噪比分析用于描述测量的可靠性:关于 MSI 和/或 MMR 测试的指南建议支持该指标的规范。表面效度测试表明,该指标可以区分所提供的医疗质量。测量规范所要求的数据元素是可获取的,这支持了测量的可行性。可靠性测试表明,测量得分的差异可归因于绩效的实际差异,而不是评分的随机变化:结直肠癌、子宫内膜癌、胃食管癌或小肠癌中的错配修复或微卫星不稳定性生物标记物检测状态的措施规定适当,测试表明该措施非常适合用于描述病理学家交流 MMR 和/或 MSI 状态的质量。
{"title":"Creation of a Quality Payment Program Measure for Mismatch Repair or Microsatellite Instability Biomarker Testing Status in Colorectal, Endometrial, Gastroesophageal, or Small Bowel Carcinoma.","authors":"Gregary T Bocsi, Jennifer Laudadio, Richa Jain, Sarah M Eakin, Amarpreet Bhalla, Jonathan A Rosenberg, Jennifer K Maratt, Sonia S Kupfer, David A Leiman, Diana M Cardona","doi":"10.5858/arpa.2022-0418-OA","DOIUrl":"10.5858/arpa.2022-0418-OA","url":null,"abstract":"<p><strong>Context.—: </strong>Quality measures that are supported by evidence-based clinical practice guidelines are preferred for assessing the quality of pathologists' practices. Careful testing of a measure ensures that scores obtained by that measure reflect the quality of a pathologist's practice.</p><p><strong>Objective.—: </strong>To specify a new quality measure and to demonstrate through testing that it is suitable for measuring pathologists' appropriate incorporation of information regarding microsatellite instability (MSI) and/or mismatch repair (MMR) status in pathology reports for colorectal, endometrial, gastroesophageal, and small bowel carcinoma.</p><p><strong>Design.—: </strong>The College of American Pathologists collaborated with the American Gastroenterological Association to specify and test the new measure. Face validity testing was used to investigate the validity of the measure. Feasibility testing was conducted to understand if data elements required by the measure specification were readily accessible. Signal-to-noise analysis was used to characterize the measure's reliability.</p><p><strong>Results.—: </strong>Guideline recommendations for MSI and/or MMR testing supported specifications for the measure. Face validity testing indicated that the measure could distinguish the quality of care provided. Data elements required by the measure specification were found to be accessible, which supported the measure's feasibility. Reliability testing showed that differences in measure score were attributable to real differences in performance rather than random variation in scoring.</p><p><strong>Conclusions.—: </strong>The Mismatch Repair or Microsatellite Instability Biomarker Testing Status in Colorectal Carcinoma, Endometrial, Gastroesophageal, or Small Bowel Carcinoma measure was appropriately specified, and testing demonstrated that it is well suited for characterizing the quality of pathologists' communication of MMR and/or MSI status.</p>","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"728-734"},"PeriodicalIF":3.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10296120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pancreaticobiliary Cytology Practice in 2021: Results of a College of American Pathologists Survey. 2021 年的胰胆细胞学实践:美国病理学家学会调查结果。
IF 3.7 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-06-01 DOI: 10.5858/arpa.2023-0167-CP
Zaibo Li, Sana O Tabbara, Ann Nwosu, Rhona J Souers, Abha Goyal, Elizabeth M Kurian, Xiaoqi Lin, Christopher VandenBussche, Lananh N Nguyen

Context.—: The College of American Pathologists (CAP) surveys provide national benchmarks of pathology practice.

Objective.—: To investigate pancreaticobiliary cytology practice in domestic and international laboratories in 2021.

Design.—: We analyzed data from the CAP Pancreaticobiliary Cytology Practice Supplemental Questionnaire that was distributed to laboratories participating in the 2021 CAP Nongynecologic Cytopathology Education Program.

Results.—: Ninety-three percent (567 of 612) of respondent laboratories routinely evaluated pancreaticobiliary cytology specimens. Biliary brushing (85%) was the most common pancreaticobiliary cytology specimen evaluated, followed by pancreatic fine-needle aspiration (79%). The most used sampling methods reported by 235 laboratories were 22-gauge needle for fine-needle aspiration (62%) and SharkCore needle for fine-needle biopsy (27%). Cell block was the most used slide preparation method (76%), followed by liquid-based cytology (59%) for pancreatic cystic lesions. Up to 95% (303 of 320) of laboratories performed rapid on-site evaluation (ROSE) on pancreatic solid lesions, while 56% (180 of 320) performed ROSE for cystic lesions. Thirty-six percent (193 of 530) of laboratories used the Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology in 2021. Among all institution types, significant differences in specimen volume, specimen type, ROSE practice, and case sign-out were identified. Additionally, significant differences in specimen type, slide preparation, and ROSE practice were found.

Conclusions.—: This is the first survey from the CAP to investigate pancreaticobiliary cytology practice. The findings reveal significant differences among institution types and between domestic and international laboratories. These data provide a baseline for future studies in a variety of practice settings.

背景美国病理学家学会(CAP)的调查提供了病理学实践的国家基准:调查 2021 年国内外实验室的胰胆管细胞学实践:我们分析了CAP胰胆细胞学实践补充问卷中的数据,该问卷已分发给参与2021年CAP非妇科细胞病理学教育计划的实验室:93%的受访实验室(612 家实验室中的 567 家)对胰胆管细胞学标本进行常规评估。胆道刷片(85%)是最常用的胰胆细胞学标本,其次是胰腺细针穿刺(79%)。235 家实验室报告的最常用取样方法是 22 号针细针穿刺(62%)和鲨鱼芯针细针活检(27%)。细胞块是胰腺囊性病变最常用的切片制备方法(76%),其次是液基细胞学(59%)。高达 95% 的实验室(320 家实验室中的 303 家)对胰腺实体病变进行了快速现场评估 (ROSE),而 56% 的实验室(320 家实验室中的 180 家)对胰腺囊性病变进行了 ROSE。36%的实验室(530 家中的 193 家)在 2021 年使用了巴氏细胞病理学会的胰胆管细胞学报告系统。在所有机构类型中,标本量、标本类型、ROSE实践和病例签出均存在显著差异。此外,在标本类型、玻片制备和ROSE实践方面也发现了明显差异:这是 CAP 首次对胰胆细胞学实践进行调查。结论:这是 CAP 首次对胰胆管细胞学实践进行调查,调查结果显示了不同机构类型之间以及国内外实验室之间的显著差异。这些数据为今后在各种实践环境中开展研究提供了基线。
{"title":"Pancreaticobiliary Cytology Practice in 2021: Results of a College of American Pathologists Survey.","authors":"Zaibo Li, Sana O Tabbara, Ann Nwosu, Rhona J Souers, Abha Goyal, Elizabeth M Kurian, Xiaoqi Lin, Christopher VandenBussche, Lananh N Nguyen","doi":"10.5858/arpa.2023-0167-CP","DOIUrl":"10.5858/arpa.2023-0167-CP","url":null,"abstract":"<p><strong>Context.—: </strong>The College of American Pathologists (CAP) surveys provide national benchmarks of pathology practice.</p><p><strong>Objective.—: </strong>To investigate pancreaticobiliary cytology practice in domestic and international laboratories in 2021.</p><p><strong>Design.—: </strong>We analyzed data from the CAP Pancreaticobiliary Cytology Practice Supplemental Questionnaire that was distributed to laboratories participating in the 2021 CAP Nongynecologic Cytopathology Education Program.</p><p><strong>Results.—: </strong>Ninety-three percent (567 of 612) of respondent laboratories routinely evaluated pancreaticobiliary cytology specimens. Biliary brushing (85%) was the most common pancreaticobiliary cytology specimen evaluated, followed by pancreatic fine-needle aspiration (79%). The most used sampling methods reported by 235 laboratories were 22-gauge needle for fine-needle aspiration (62%) and SharkCore needle for fine-needle biopsy (27%). Cell block was the most used slide preparation method (76%), followed by liquid-based cytology (59%) for pancreatic cystic lesions. Up to 95% (303 of 320) of laboratories performed rapid on-site evaluation (ROSE) on pancreatic solid lesions, while 56% (180 of 320) performed ROSE for cystic lesions. Thirty-six percent (193 of 530) of laboratories used the Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology in 2021. Among all institution types, significant differences in specimen volume, specimen type, ROSE practice, and case sign-out were identified. Additionally, significant differences in specimen type, slide preparation, and ROSE practice were found.</p><p><strong>Conclusions.—: </strong>This is the first survey from the CAP to investigate pancreaticobiliary cytology practice. The findings reveal significant differences among institution types and between domestic and international laboratories. These data provide a baseline for future studies in a variety of practice settings.</p>","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"677-685"},"PeriodicalIF":3.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10215365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Implementation of Nongynecologic Reporting Systems in Cytopathology Laboratories Is Highly Variable: Analysis of Data From a 2020 Supplemental Survey of Participants in the College of American Pathologists Interlaboratory Comparison Program in Nongynecologic Cytology. 细胞病理学实验室非妇科报告系统的实施情况千差万别:美国病理学家学会非妇科细胞学实验室间比较计划 2020 年参与者补充调查数据分析》(College of American Pathologists Interlaboratory Comparison Program in Nongynecologic Cytology)。
IF 3.7 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-05-01 DOI: 10.5858/arpa.2023-0010-CP
Christopher J VandenBussche, Ann Nwosu, Rhona Souers, Kaitlin E Sundling, Jennifer Brainard, Abha Goyal, Xiaoqi Lin, Shala Masood, Lananh Nguyen, Janie Roberson, Sana O Tabbara, Christine Booth

Context: In recent years, several reporting systems have been developed by national and international cytopathology organizations to standardize the evaluation of specific cytopathology specimen types.

Objective: To assess the current implementation rates, implementation methods, and barriers to implementation of commonly used nongynecologic reporting systems in cytopathology laboratories.

Design: Data were analyzed from a survey developed by the College of American Pathologists Cytopathology Committee and distributed to participants in the College of American Pathologists Nongynecologic Cytopathology Education Program mailing.

Results: Nongynecologic reporting systems with the highest rate of adoption were the Bethesda System for Reporting Thyroid Cytopathology, 2nd edition (74.1%; 552 of 745); the Paris System for Reporting Urinary Cytology (53.9%; 397 of 736); and the Milan System for Reporting Salivary Gland Cytopathology (29.1%; 200 of 688). The most common reason given for not adopting a reporting system was satisfaction with a laboratory's current system. Implementation varied among laboratories with regard to which stakeholders were involved in deciding to implement a system and the amount of education provided during the implementation process.

Conclusions: The implementation of nongynecologic reporting systems in cytopathology laboratories was highly variable.

背景:近年来,国内和国际细胞病理学组织开发了多种报告系统,以规范对特定细胞病理学标本类型的评估:目的:评估目前细胞病理学实验室常用的非妇科报告系统的实施率、实施方法和实施障碍:数据由美国病理学家学会细胞病理学委员会制定,并分发给美国病理学家学会非妇科细胞病理学教育计划邮件的参与者:非妇科细胞病理学报告系统采用率最高的是贝塞斯达甲状腺细胞病理学报告系统第 2 版(74.1%;745 例中的 552 例)、巴黎泌尿系统细胞病理学报告系统(53.9%;736 例中的 397 例)和米兰唾液腺细胞病理学报告系统(29.1%;688 例中的 200 例)。不采用报告系统的最常见原因是对实验室现有系统的满意度。各实验室的实施情况各不相同,这与哪些利益相关者参与了实施系统的决定以及在实施过程中提供的教育程度有关:结论:细胞病理实验室非妇科报告系统的实施情况差异很大。
{"title":"The Implementation of Nongynecologic Reporting Systems in Cytopathology Laboratories Is Highly Variable: Analysis of Data From a 2020 Supplemental Survey of Participants in the College of American Pathologists Interlaboratory Comparison Program in Nongynecologic Cytology.","authors":"Christopher J VandenBussche, Ann Nwosu, Rhona Souers, Kaitlin E Sundling, Jennifer Brainard, Abha Goyal, Xiaoqi Lin, Shala Masood, Lananh Nguyen, Janie Roberson, Sana O Tabbara, Christine Booth","doi":"10.5858/arpa.2023-0010-CP","DOIUrl":"10.5858/arpa.2023-0010-CP","url":null,"abstract":"<p><strong>Context: </strong>In recent years, several reporting systems have been developed by national and international cytopathology organizations to standardize the evaluation of specific cytopathology specimen types.</p><p><strong>Objective: </strong>To assess the current implementation rates, implementation methods, and barriers to implementation of commonly used nongynecologic reporting systems in cytopathology laboratories.</p><p><strong>Design: </strong>Data were analyzed from a survey developed by the College of American Pathologists Cytopathology Committee and distributed to participants in the College of American Pathologists Nongynecologic Cytopathology Education Program mailing.</p><p><strong>Results: </strong>Nongynecologic reporting systems with the highest rate of adoption were the Bethesda System for Reporting Thyroid Cytopathology, 2nd edition (74.1%; 552 of 745); the Paris System for Reporting Urinary Cytology (53.9%; 397 of 736); and the Milan System for Reporting Salivary Gland Cytopathology (29.1%; 200 of 688). The most common reason given for not adopting a reporting system was satisfaction with a laboratory's current system. Implementation varied among laboratories with regard to which stakeholders were involved in deciding to implement a system and the amount of education provided during the implementation process.</p><p><strong>Conclusions: </strong>The implementation of nongynecologic reporting systems in cytopathology laboratories was highly variable.</p>","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"531-537"},"PeriodicalIF":3.7,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10096357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Reassessment of the Impact and Significance of Social Media to Pathology. 重新评估社交媒体对病理学的影响和意义。
IF 4.6 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-05-01 DOI: 10.5858/arpa.2022-0463-RA
Stephanie J T Chen, Megan I Samuelson, Anand Rajan Kd

Context: Social media (SM) use in pathology and medicine today is widespread, receives active advocacy, and is said to bring a host of benefits. In latter days, the harmful effects of SM have received attention, but they have yet been followed by greater encouragement of professionalized SM usage. SM use in medicine has seen adoption in parallel to its general ascendancy, even though the platforms are products with purposes misaligned with the practice of medicine.

Objective: To (1) characterize premises and forces that propel professional SM platform adoption and use, and (2) examine wide-ranging literature, both medical and nonmedical, that substantiates the premises and to find counteracting perspectives and evidence.

Data sources: Review of the literature using relevant keyword searches in PubMed, Google Scholar, Dimensions, and Web of Science for articles that study/describe professional SM use in pathology and medicine. Additionally, we examined business, technology, and social sciences literature and high-quality gray literature (newspapers, books, blogs) that addressed questions in relation to the topic of professional SM adoption.

Conclusions: We identified 6 major premises as motivators of professional SM use and highlight significant counteracting factors. We conclude that the harms of professionalized SM use have not been fully considered in the medical literature and that a change in direction and the creation of new communication platforms would be beneficial.

背景:如今,病理学和医学界对社交媒体(SM)的使用非常普遍,并得到了积极的倡导,据说能带来诸多益处。近来,社交媒体的有害影响受到关注,但随之而来的是对社交媒体专业化使用的更大鼓励。尽管这些平台是与医学实践目的不符的产品,但在医学中使用 SM 的情况与 SM 的普遍兴起并行不悖:目的:(1) 描述推动专业 SM 平台采纳和使用的前提和力量,(2) 研究证实这些前提的医学和非医学方面的大量文献,并寻找反驳观点和证据:通过在 PubMed、Google Scholar、Dimensions 和 Web of Science 中搜索相关关键词,查阅研究/描述病理学和医学专业 SM 使用情况的文献。此外,我们还研究了商业、技术和社会科学文献以及高质量的灰色文献(报纸、书籍、博客),这些文献都涉及了与专业 SM 应用主题相关的问题:我们确定了专业 SM 使用动机的 6 个主要前提,并强调了重要的抵消因素。我们的结论是,医学文献尚未充分考虑专业化 SM 使用的危害,改变方向和创建新的交流平台将是有益的。
{"title":"A Reassessment of the Impact and Significance of Social Media to Pathology.","authors":"Stephanie J T Chen, Megan I Samuelson, Anand Rajan Kd","doi":"10.5858/arpa.2022-0463-RA","DOIUrl":"10.5858/arpa.2022-0463-RA","url":null,"abstract":"<p><strong>Context: </strong>Social media (SM) use in pathology and medicine today is widespread, receives active advocacy, and is said to bring a host of benefits. In latter days, the harmful effects of SM have received attention, but they have yet been followed by greater encouragement of professionalized SM usage. SM use in medicine has seen adoption in parallel to its general ascendancy, even though the platforms are products with purposes misaligned with the practice of medicine.</p><p><strong>Objective: </strong>To (1) characterize premises and forces that propel professional SM platform adoption and use, and (2) examine wide-ranging literature, both medical and nonmedical, that substantiates the premises and to find counteracting perspectives and evidence.</p><p><strong>Data sources: </strong>Review of the literature using relevant keyword searches in PubMed, Google Scholar, Dimensions, and Web of Science for articles that study/describe professional SM use in pathology and medicine. Additionally, we examined business, technology, and social sciences literature and high-quality gray literature (newspapers, books, blogs) that addressed questions in relation to the topic of professional SM adoption.</p><p><strong>Conclusions: </strong>We identified 6 major premises as motivators of professional SM use and highlight significant counteracting factors. We conclude that the harms of professionalized SM use have not been fully considered in the medical literature and that a change in direction and the creation of new communication platforms would be beneficial.</p>","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"613-622"},"PeriodicalIF":4.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10101803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation of Red Blood Cell Casts With Renal Dysfunction in Patients With Infection-Related Glomerulonephritis. 感染性肾小球肾炎患者红细胞铸型与肾功能障碍的相关性
IF 4.6 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-05-01 DOI: 10.5858/arpa.2022-0514-OA
Mineaki Kitamura, Laura Biederman, Dalia Ibrahim, Tibor Nadasdy, Sergey V Brodsky, Anjali A Satoskar

Context: Infection-related glomerulonephritis (IRGN) usually manifests as a proliferative immune-complex glomerulonephritis. The degree of renal dysfunction at presentation can vary. Association with histologic features on kidney biopsy remains unknown.

Objective: To study the correlation between renal function in IRGN at the time of biopsy and the severity of histologic features.

Design: Culture-proven IRGN cases at our facility were included and divided based on estimated glomerular filtration rate (eGFR) 15 ml/min/1.73 m2. Patients' demographic and pathologic findings were obtained from electronic medical records and kidney biopsy reports.

Results: In total, 104 cases were diagnosed with IRGN on biopsy (mean age, 55.6 ± 15.6 years; male, n = 79 [76%]; median eGFR, 14.5 mL/min/1.73 m2), and 51 of 104 showed eGFR <15 mL/min/1.73 m2. Among all the histologic features assessed, only percent tubules with red blood cell (RBC) casts showed statistical difference, being significantly higher in the lower-eGFR group (P = .004). Multivariable logistic regression analysis also showed that %tubules with RBC casts were associated with lower eGFR (odds ratio, 1.12; 95% CI, 1.01-1.24; P = .01). Patients with 5% or more RBC casts (n = 31) showed a lower eGFR (P = .02) and a higher %cellular crescent (P < .001) compared with those with less than 5% RBC casts. Patients with concomitant anticoagulant therapy (n = 11) showed higher percentages of RBC casts than those without anticoagulants (P = .02).

Conclusions: Particular attention to the extent of RBC casts on kidney biopsy is recommended in patients with IRGN because these portend worse renal dysfunction, more so in patients requiring anticoagulation (including for hemodialysis) because they are especially vulnerable to developing anticoagulant-related nephropathy.

背景:感染相关性肾小球肾炎(IRGN)通常表现为增殖性免疫复合物性肾小球肾炎。发病时肾功能不全的程度各不相同。其与肾活检组织学特征的关系尚不清楚:研究IRGN活检时肾功能与组织学特征严重程度之间的相关性:设计:纳入我院经培养证实的 IRGN 病例,并根据估计肾小球滤过率(eGFR)15 ml/min/1.73 m2 进行划分。从电子病历和肾活检报告中获取患者的人口统计学和病理学结果:结果:共有 104 例经活检确诊为 IRGN(平均年龄为 55.6 ± 15.6 岁;男性,n = 79 [76%];eGFR 中位数为 14.5 mL/min/1.73 m2),104 例中有 51 例得出了 eGFR 结论:建议IRGN患者特别注意肾活检中红细胞铸型的程度,因为这些铸型预示着更严重的肾功能障碍,尤其是需要抗凝治疗(包括血液透析)的患者,因为他们特别容易发生与抗凝剂相关的肾病。
{"title":"Correlation of Red Blood Cell Casts With Renal Dysfunction in Patients With Infection-Related Glomerulonephritis.","authors":"Mineaki Kitamura, Laura Biederman, Dalia Ibrahim, Tibor Nadasdy, Sergey V Brodsky, Anjali A Satoskar","doi":"10.5858/arpa.2022-0514-OA","DOIUrl":"10.5858/arpa.2022-0514-OA","url":null,"abstract":"<p><strong>Context: </strong>Infection-related glomerulonephritis (IRGN) usually manifests as a proliferative immune-complex glomerulonephritis. The degree of renal dysfunction at presentation can vary. Association with histologic features on kidney biopsy remains unknown.</p><p><strong>Objective: </strong>To study the correlation between renal function in IRGN at the time of biopsy and the severity of histologic features.</p><p><strong>Design: </strong>Culture-proven IRGN cases at our facility were included and divided based on estimated glomerular filtration rate (eGFR) 15 ml/min/1.73 m2. Patients' demographic and pathologic findings were obtained from electronic medical records and kidney biopsy reports.</p><p><strong>Results: </strong>In total, 104 cases were diagnosed with IRGN on biopsy (mean age, 55.6 ± 15.6 years; male, n = 79 [76%]; median eGFR, 14.5 mL/min/1.73 m2), and 51 of 104 showed eGFR <15 mL/min/1.73 m2. Among all the histologic features assessed, only percent tubules with red blood cell (RBC) casts showed statistical difference, being significantly higher in the lower-eGFR group (P = .004). Multivariable logistic regression analysis also showed that %tubules with RBC casts were associated with lower eGFR (odds ratio, 1.12; 95% CI, 1.01-1.24; P = .01). Patients with 5% or more RBC casts (n = 31) showed a lower eGFR (P = .02) and a higher %cellular crescent (P < .001) compared with those with less than 5% RBC casts. Patients with concomitant anticoagulant therapy (n = 11) showed higher percentages of RBC casts than those without anticoagulants (P = .02).</p><p><strong>Conclusions: </strong>Particular attention to the extent of RBC casts on kidney biopsy is recommended in patients with IRGN because these portend worse renal dysfunction, more so in patients requiring anticoagulation (including for hemodialysis) because they are especially vulnerable to developing anticoagulant-related nephropathy.</p>","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"545-552"},"PeriodicalIF":4.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10124079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atypical Droplet Digital Polymerase Chain Reaction Patterns That Indicate Uncommon but Clinically Actionable EGFR Mutations in Lung Cancer. 非典型液滴数字聚合酶链反应模式表明肺癌中的表皮生长因子受体(EGFR)突变并不常见,但在临床上却具有可操作性。
IF 4.6 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-05-01 DOI: 10.5858/arpa.2023-0088-OA
Adam Lechner, Anooja Rai, Vanesa Rojas-Rudilla, Yanan Kuang, Cloud P Paweletz, Lynette M Sholl, Fei Dong

Context: Droplet digital polymerase chain reaction (ddPCR) is a sensitive method to detect common pathogenic EGFR mutations in non-small cell lung cancer. Although targeted assays have not been specifically designed to detect them, uncommon EGFR mutations have been linked to response to targeted therapy.

Objective: To describe atypical ddPCR patterns that correspond to uncommon but clinically actionable EGFR mutations.

Design: A cohort of 1134 consecutive non-small cell lung cancers that underwent targeted next-generation sequencing was reviewed. Uncommon EGFR mutations involving probe binding sites were evaluated by ddPCR.

Results: Two hundred fifty-five of 1134 cancers (22.5%) harbored pathogenic EGFR mutations. One hundred eighty-six of 255 (72.9%) had canonical EGFR exon 19 deletion or exon 21 p.L858R variants designed for detection by ddPCR. An additional 25 of 255 cases (9.8%) had uncommon EGFR mutations within the probe-binding site, including 1 case with concurrent uncommon mutations in both exon 19 and exon 21. These mutations included uncommon EGFR exon 19 deletions (n = 6), EGFR exon 19 substitutions p.L747P (n = 3) and p.L747A (n = 1), dinucleotide substitutions leading to EGFR p.L858R (n = 5), EGFR exon 21 substitutions p.K860I (n = 1) and p.L861Q (n = 9), and EGFR p.[L858R;K860I] (n = 1). Droplet digital polymerase chain reaction generated atypical but reproducible signal for each of these uncommon variants.

Conclusions: Droplet digital polymerase chain reaction analysis of uncommon pathogenic EGFR variants can yield unique and reproducible results. Recognition of atypical patterns in EGFR ddPCR testing can prompt confirmatory molecular testing and aid appropriate targeted therapy selection for patients with non-small cell lung cancer.

背景:液滴数字聚合酶链反应(ddPCR)是检测非小细胞肺癌中常见表皮生长因子受体(EGFR)致病突变的灵敏方法。虽然还没有专门用于检测这些突变的靶向测定,但不常见的表皮生长因子受体突变与靶向治疗的反应有关:目的:描述与不常见但临床上可行的表皮生长因子受体突变相对应的非典型 ddPCR 模式:设计:研究人员回顾了1134例连续接受新一代靶向测序的非小细胞肺癌患者。通过 ddPCR 评估了涉及探针结合位点的不常见表皮生长因子受体突变:结果:1134 例癌症中有 255 例(22.5%)存在致病性表皮生长因子受体突变。255例癌症中有186例(72.9%)存在典型的表皮生长因子受体第19外显子缺失或第21外显子p.L858R变异,可通过ddPCR进行检测。在 255 个病例中,另有 25 个病例(9.8%)在探针结合位点内发生了不常见的表皮生长因子受体突变,其中 1 个病例的第 19 号外显子和第 21 号外显子同时发生了不常见的突变。这些突变包括不常见的表皮生长因子受体第19外显子缺失(n = 6)、表皮生长因子受体第19外显子置换p.L747P(n = 3)和p.L747A(n = 1)、导致表皮生长因子受体p.L858R的二核苷酸置换(n = 5)、表皮生长因子受体第21外显子置换p.K860I(n = 1)和p.L861Q(n = 9)以及表皮生长因子受体p.[L858R;K860I](n = 1)。液滴数字聚合酶链反应为这些不常见的变异产生了非典型但可重复的信号:结论:对不常见的致病性表皮生长因子受体变体进行液滴数字聚合酶链反应分析可产生独特且可重复的结果。识别表皮生长因子受体 ddPCR 检测中的非典型模式可促使进行确证分子检测,帮助非小细胞肺癌患者选择适当的靶向治疗。
{"title":"Atypical Droplet Digital Polymerase Chain Reaction Patterns That Indicate Uncommon but Clinically Actionable EGFR Mutations in Lung Cancer.","authors":"Adam Lechner, Anooja Rai, Vanesa Rojas-Rudilla, Yanan Kuang, Cloud P Paweletz, Lynette M Sholl, Fei Dong","doi":"10.5858/arpa.2023-0088-OA","DOIUrl":"10.5858/arpa.2023-0088-OA","url":null,"abstract":"<p><strong>Context: </strong>Droplet digital polymerase chain reaction (ddPCR) is a sensitive method to detect common pathogenic EGFR mutations in non-small cell lung cancer. Although targeted assays have not been specifically designed to detect them, uncommon EGFR mutations have been linked to response to targeted therapy.</p><p><strong>Objective: </strong>To describe atypical ddPCR patterns that correspond to uncommon but clinically actionable EGFR mutations.</p><p><strong>Design: </strong>A cohort of 1134 consecutive non-small cell lung cancers that underwent targeted next-generation sequencing was reviewed. Uncommon EGFR mutations involving probe binding sites were evaluated by ddPCR.</p><p><strong>Results: </strong>Two hundred fifty-five of 1134 cancers (22.5%) harbored pathogenic EGFR mutations. One hundred eighty-six of 255 (72.9%) had canonical EGFR exon 19 deletion or exon 21 p.L858R variants designed for detection by ddPCR. An additional 25 of 255 cases (9.8%) had uncommon EGFR mutations within the probe-binding site, including 1 case with concurrent uncommon mutations in both exon 19 and exon 21. These mutations included uncommon EGFR exon 19 deletions (n = 6), EGFR exon 19 substitutions p.L747P (n = 3) and p.L747A (n = 1), dinucleotide substitutions leading to EGFR p.L858R (n = 5), EGFR exon 21 substitutions p.K860I (n = 1) and p.L861Q (n = 9), and EGFR p.[L858R;K860I] (n = 1). Droplet digital polymerase chain reaction generated atypical but reproducible signal for each of these uncommon variants.</p><p><strong>Conclusions: </strong>Droplet digital polymerase chain reaction analysis of uncommon pathogenic EGFR variants can yield unique and reproducible results. Recognition of atypical patterns in EGFR ddPCR testing can prompt confirmatory molecular testing and aid appropriate targeted therapy selection for patients with non-small cell lung cancer.</p>","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"553-558"},"PeriodicalIF":4.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10483879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RNA Sequencing for Solid Tumor Fusion Gene Detection: Proficiency Testing Practice and Performance Comparison. 用于实体瘤融合基因检测的 RNA 测序:能力验证实践与性能比较。
IF 4.6 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-05-01 DOI: 10.5858/arpa.2023-0047-CP
Julia A Bridge, Kevin C Halling, Joel T Moncur, Rhona J Souers, Meera R Hameed, Helen Fernandes, Angshumoy Roy, Lea Surrey, Laura J Tafe, Patricia Vasalos, Dolores H Lopez-Terrada

Context: Next-generation sequencing-based approaches using RNA have increasingly been used by clinical laboratories for the detection of fusion genes, intragenic rearrangements, and exon-skipping events. Correspondingly, the College of American Pathologists (CAP) has advanced RNA sequencing proficiency testing (PT) to ensure optimal performance of these assays.

Objective: To report on laboratory performance and practices of RNA sequencing for the detection of fusion genes, intragenic rearrangements, and exon-skipping events using CAP PT data from 8 mailings (2018-A through 2021-B).

Design: CAP PT RNA sequencing program results from 153 laboratories across 24 proficiency test specimens, interrogating 22 distinct engineered fusion transcripts, were analyzed for correct identification of the fusion event, associated performance variables, and laboratory practices.

Results: Overall, the 4-year program detection rate (sensitivity) was 95.5% (1486 of 1556 results). False-negative rates were 3.6% (53 of 1463) and 18.3% (17 of 93) for fusion gene and intragenic rearrangement/exon-skipping events, respectively. Only 19 false-positive results were reported among the 8 PT mailings, and most were likely the result of preanalytical or postanalytical errors. There were no practice characteristics (eg, instrumentation, sequencing method) significantly associated with the fusion detection results.

Conclusions: These data reveal a high overall sensitivity and specificity for fusion gene detection by participating laboratories using clinical RNA sequencing. Performance was comparable across all laboratories, regardless of methodology. The fraction of false-negative results for intragenic rearrangement/exon-skipping events was greater than that for the chimeric fusion genes. False-negative results could not be attributed to any specific practice characteristics.

背景:临床实验室越来越多地使用基于下一代RNA测序的方法来检测融合基因、基因内重排和外显子缺失事件。相应地,美国病理学家学会(CAP)推进了 RNA 测序能力验证(PT),以确保这些检测方法的最佳性能:利用 8 次邮件(2018-A 至 2021-B)中的 CAP PT 数据,报告用于检测融合基因、基因内重排和外显子跳断事件的 RNA 测序的实验室性能和实践:对来自 153 个实验室的 24 份能力验证样本的 CAP PT RNA 测序项目结果进行了分析,其中涉及 22 个不同的工程融合转录本,分析了融合事件的正确识别、相关性能变量和实验室实践:总体而言,4 年计划的检测率(灵敏度)为 95.5%(1556 项结果中的 1486 项)。融合基因和基因内重排/外显子缺失事件的假阴性率分别为 3.6%(1463 项中的 53 项)和 18.3%(93 项中的 17 项)。在 8 份 PT 邮件中,仅报告了 19 个假阳性结果,其中大部分可能是分析前或分析后出错所致。没有任何实践特征(如仪器、测序方法)与融合检测结果显著相关:这些数据显示,参与研究的实验室使用临床RNA测序法检测融合基因的总体灵敏度和特异性都很高。无论采用哪种方法,所有实验室的检测结果都具有可比性。基因内重排/外显子缺失事件的假阴性结果比例高于嵌合型融合基因。假阴性结果不能归因于任何特定的实践特点。
{"title":"RNA Sequencing for Solid Tumor Fusion Gene Detection: Proficiency Testing Practice and Performance Comparison.","authors":"Julia A Bridge, Kevin C Halling, Joel T Moncur, Rhona J Souers, Meera R Hameed, Helen Fernandes, Angshumoy Roy, Lea Surrey, Laura J Tafe, Patricia Vasalos, Dolores H Lopez-Terrada","doi":"10.5858/arpa.2023-0047-CP","DOIUrl":"10.5858/arpa.2023-0047-CP","url":null,"abstract":"<p><strong>Context: </strong>Next-generation sequencing-based approaches using RNA have increasingly been used by clinical laboratories for the detection of fusion genes, intragenic rearrangements, and exon-skipping events. Correspondingly, the College of American Pathologists (CAP) has advanced RNA sequencing proficiency testing (PT) to ensure optimal performance of these assays.</p><p><strong>Objective: </strong>To report on laboratory performance and practices of RNA sequencing for the detection of fusion genes, intragenic rearrangements, and exon-skipping events using CAP PT data from 8 mailings (2018-A through 2021-B).</p><p><strong>Design: </strong>CAP PT RNA sequencing program results from 153 laboratories across 24 proficiency test specimens, interrogating 22 distinct engineered fusion transcripts, were analyzed for correct identification of the fusion event, associated performance variables, and laboratory practices.</p><p><strong>Results: </strong>Overall, the 4-year program detection rate (sensitivity) was 95.5% (1486 of 1556 results). False-negative rates were 3.6% (53 of 1463) and 18.3% (17 of 93) for fusion gene and intragenic rearrangement/exon-skipping events, respectively. Only 19 false-positive results were reported among the 8 PT mailings, and most were likely the result of preanalytical or postanalytical errors. There were no practice characteristics (eg, instrumentation, sequencing method) significantly associated with the fusion detection results.</p><p><strong>Conclusions: </strong>These data reveal a high overall sensitivity and specificity for fusion gene detection by participating laboratories using clinical RNA sequencing. Performance was comparable across all laboratories, regardless of methodology. The fraction of false-negative results for intragenic rearrangement/exon-skipping events was greater than that for the chimeric fusion genes. False-negative results could not be attributed to any specific practice characteristics.</p>","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"538-544"},"PeriodicalIF":4.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9933558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Archives of pathology & laboratory medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1